‘Phototherapy technology can completely eliminate cancer cells by reducing the pain of chemotherapy and minimizing side effects after treatment. This technology utilizes peptide that specifically targets cancer cells, leaving the normal cells unaffected.’
The conventional photosensitizers had to be administered repeatedly as their effect lasted for only one session. The residual deposits of these photosensitizers after treatment were accumulated in the skin or eyes causing side effects due to light.
However recently developed photosensitizers with phototherapeutic effects use the
internalizing RGD peptide (iRGD) that can selectively penetrate and get activated only in cancer tissues.
This newly developed
photosensitizer upon being injected into a living body, is activated by the body temperature and aggregates into a supramolecular array designed by the research team, to be stored around cancer cells. This destroys only cancer cells without harming normal cells.
The efficacy of the phototherapeutic agent was demonstrated in a mouse model implanted with a tumor. The photosensitizer was stored around the tumor and was continuously released for a long time (2 to 4 weeks), demonstrating the ability of selectively targeting the tumor with just one injection around the cancerous tissues.
It also showed no toxicity for the tissues and major organs around the cancer, even with repeated exposure to light after which, there was
complete removal of cancerous tissues.
"We developed a cancer-targeting peptide phototherapeutic agent that forms a reservoir through supramolecular self-assembly without additional adjuvants when injected in vivo. The developed phototherapeutic agent is expected to be useful in future phototherapy as it allows long-term repeated phototherapy without toxicity after only one injection around the cancer until the complete removal of the cancer, and has a simple formulation with a single component," says KIST Center Director Se-hoon Kim.
Source: Medindia
